Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

David Brendan Price, D. Dutchman, A. Mawson, B. Bodalia, S. Duggan, P. Todd, FLOW Res Grp

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Previous studies have indicated the benefits of adding long acting beta(2) agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied.

Methods: After a run in period of 7-14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 mug twice daily together with either eformoterol Turbohaler 9 mug (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 mug daily and either eformoterol 9 mug or placebo twice daily for a further 6 months.

Results: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief beta(2) agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7,2 versus 10.5 per patient, 95% confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).

Conclusions: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.

Original languageEnglish
Pages (from-to)791-798
Number of pages7
JournalThorax
Volume57
Issue number9
DOIs
Publication statusPublished - 2002

Keywords

  • QUALITY-OF-LIFE
  • FORMOTEROL
  • ONSET
  • DURATION
  • QUESTIONNAIRE
  • TURBUHALER(R)
  • SALMETEROL

Cite this

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. / Price, David Brendan; Dutchman, D.; Mawson, A.; Bodalia, B.; Duggan, S.; Todd, P.; FLOW Res Grp.

In: Thorax, Vol. 57, No. 9, 2002, p. 791-798.

Research output: Contribution to journalArticle

Price, DB, Dutchman, D, Mawson, A, Bodalia, B, Duggan, S, Todd, P & FLOW Res Grp 2002, 'Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose', Thorax, vol. 57, no. 9, pp. 791-798. https://doi.org/10.1136/thorax.57.9.791
Price, David Brendan ; Dutchman, D. ; Mawson, A. ; Bodalia, B. ; Duggan, S. ; Todd, P. ; FLOW Res Grp. / Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. In: Thorax. 2002 ; Vol. 57, No. 9. pp. 791-798.
@article{bbea1872099142b0916e0d8811fd727c,
title = "Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose",
abstract = "Background: Previous studies have indicated the benefits of adding long acting beta(2) agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied.Methods: After a run in period of 7-14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 mug twice daily together with either eformoterol Turbohaler 9 mug (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 mug daily and either eformoterol 9 mug or placebo twice daily for a further 6 months.Results: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief beta(2) agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7,2 versus 10.5 per patient, 95{\%} confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).Conclusions: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.",
keywords = "QUALITY-OF-LIFE, FORMOTEROL, ONSET, DURATION, QUESTIONNAIRE, TURBUHALER(R), SALMETEROL",
author = "Price, {David Brendan} and D. Dutchman and A. Mawson and B. Bodalia and S. Duggan and P. Todd and {FLOW Res Grp}",
year = "2002",
doi = "10.1136/thorax.57.9.791",
language = "English",
volume = "57",
pages = "791--798",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group Ltd",
number = "9",

}

TY - JOUR

T1 - Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

AU - Price, David Brendan

AU - Dutchman, D.

AU - Mawson, A.

AU - Bodalia, B.

AU - Duggan, S.

AU - Todd, P.

AU - FLOW Res Grp

PY - 2002

Y1 - 2002

N2 - Background: Previous studies have indicated the benefits of adding long acting beta(2) agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied.Methods: After a run in period of 7-14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 mug twice daily together with either eformoterol Turbohaler 9 mug (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 mug daily and either eformoterol 9 mug or placebo twice daily for a further 6 months.Results: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief beta(2) agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7,2 versus 10.5 per patient, 95% confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).Conclusions: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.

AB - Background: Previous studies have indicated the benefits of adding long acting beta(2) agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied.Methods: After a run in period of 7-14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 mug twice daily together with either eformoterol Turbohaler 9 mug (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 mug daily and either eformoterol 9 mug or placebo twice daily for a further 6 months.Results: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief beta(2) agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7,2 versus 10.5 per patient, 95% confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).Conclusions: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.

KW - QUALITY-OF-LIFE

KW - FORMOTEROL

KW - ONSET

KW - DURATION

KW - QUESTIONNAIRE

KW - TURBUHALER(R)

KW - SALMETEROL

U2 - 10.1136/thorax.57.9.791

DO - 10.1136/thorax.57.9.791

M3 - Article

VL - 57

SP - 791

EP - 798

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 9

ER -